TXMD AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
TXMD Current Performance
2.23%
Therapeuticsmd incorporated
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to TXMD
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
SGMT | Sagimet biosciences inc | - | 1 | 3 | 2 | 1 | |
ANRO | Alto neuroscience inc | - | 3 | 2 | 3 | 1 | |
RPTX | Repare therapeutics inc | 3 | 3 | 2 | 1 | 1 | |
GLTO | Galecto inc | 2 | 3 | 2 | 1 | 1 | |
MLYS | Mineralys therapeutics inc | - | 4 | 3 | 3 | 1 |
- SGMT Sagimet biosciences incValue -Trend 1Swing Trading 3Whale Interest 2Dividend 1See more
TXMD Profile
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).